Dr. Reddy's Laboratories Limited — Important, 05-11-2024: General Updates

Dr. Reddy’s Laboratories reported robust financial results for the quarter and half-year ended September 30, 2024, achieving consolidated revenues of ₹80,162 million, a 17% year-over-year increase. The company approved a ₹600 crore investment in its Russian subsidiary for working capital needs. Highlights include a successful acquisition of Nicotine Replacement Therapy brands from Haleon and a joint venture with Nestlé for nutraceuticals. Additionally, a stock split was approved to enhance share liquidity.